Inclisiran in a real-world single-center registry of patients with very high atherosclerotic cardiovascular risk
In a real-world population 3-6 months of therapy with inclisiran provide consistent and effective reduction in LDLc levels without significant adverse side-effects.
Authors
- Andrea Cuculo
- Monica Carbonara
- Massimo Iacoviello (ORCID: https://orcid.org/0000-0001-9613-5062)
- Paola Gargiulo (ORCID: https://orcid.org/0000-0003-4622-1725)
- Natale Daniele Brunetti (ORCID: https://orcid.org/0000-0001-9610-7408)
- Giulio Campanale
- Pasquale Perrone Filardi
- S. Nuzzo (ORCID: https://orcid.org/0000-0001-5460-2638)
- Antonio Centola
Institutions
- University of Foggia (IT)
- Ospedali Riuniti di Foggia (IT)
- University of Naples Federico II (IT)
Publication Details
- Journal
- Atherosclerosis Plus
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1016/j.athplu.2025.09.001
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00